Celestica IncCLS.TOTOP PICKJun 10, 2014Stock price when the opinion was issued
As of Sep 22, 2026. Market Open.
Bottomed out. He just wrote a put on this recently. One of the cheapest on PEG that you're going to get in the space. Growing ~76%, trading at a much lower multiple than that. Highly cyclical play. Trades at 16x PE for 2027. Strong, visible growth out to 2029.
Put it in a non-registered account, where you don't mind taking some risk.
Think of it as a Canadian DELL. Largely tied to GOOG's capex, the TPU program, and networking. Benefiting from the super-cycle. Not sure inside the AI trade is the best place to park capital. As supply starts catching up with demand, chances to earn outsized margins start compressing.
Not expensive today. Don't sell. Keep an open mind to ASML or TSM (for more stability).
Very much aligned with the entire platform being built out, not just individual components. Direct exposure and concentration to the hyperscalers as customers. He thinks those capex numbers are going up, so there's still upside in this name. But with any narrative shift, this will get sold off first.
In a massive growth segment, with the AI infrastructure buildout. Strategically in a very good position. If you have your heart set on this one, valuation is very reasonable at below 20x PE. Yet FCF is fairly meagre, which indicates valuation is still stretched. Watch and wait.
Instead, he uses TSM for client portfolios. Valuations in the space tend to be fairly rich. So this name isn't a buy today. Watch and wait on this one too.
Trades at 41x PE. It comes down to whether demand will continue to rise with AI spending. If so, profits will continue to be profitable with EPS to jump from $10 in 2026 to $15 in 2027, then $19 in 2028, then $26 in 2029. CLS comes down to how much you want to pay for it. Beta is a volatile 2.04, twice as much as the TSX. So, earnings is very important.
Do outsource contract manufacturing. In the top 5% of his database. Over the last 2 years they have been diversifying away from high-volume commodity hand sets, etc., and towards a more stable and high-margin long product cycles that occur in medical and aerospace. Has a 12.5% forecast return on equity and 8.5% trailing free cash flow yield. Cash of $483 million.